In March 20th, according to the official WeChat official account of China Meheco Group Co.Ltd(600056) , in March 19th, China Meheco Group Co.Ltd(600056) ( China Meheco Group Co.Ltd(600056) ) and the first COVID-19 virus treatment drug PAXLOVID, which were co operated with Pfizer, had been transported to the Daxing logistics center of China Meheco Group Co.Ltd(600056) . All goods were closed to the whole process according to the import and export related epidemic prevention requirements, and the relevant work such as acceptance and warehousing had been completed.
China Meheco Group Co.Ltd(600056) said that at present, the company has received an urgent order for drug emergency support, and all drugs are being transported to the front line of the national anti epidemic.
China Meheco Group Co.Ltd(600056) WeChat public official account for more than 5 o’clock in the morning of March 20th. The special transport vehicle loaded with COVID-19 virus treatment drug Paxlovid starts from China Meheco Group Co.Ltd(600056) Daxing logistics center and sailed to Changchun City, Jilin Province, which marks the opening of the drug protection action of China Meheco Group Co.Ltd(600056) COVID-19 treatment support for the epidemic. The batch of drugs is expected to arrive in Changchun, Jilin Province today and will be sent to the anti epidemic front immediately after arrival.
On March 9, China Meheco Group Co.Ltd(600056) announced that the company signed a supply agreement with Pfizer on March 9, 2022. The company will be responsible for the commercial operation of Pfizer Inc COVID-19 virus PAXLOVID in Chinese mainland market during the agreement period (2022).
Paxlovid is an oral small molecule covid-19 virus therapeutic drug, which is a treatment method combined with nimatovir and ritonavir. In February 11th this year, the State Food and Drug Administration (FDA), in accordance with the relevant provisions of the drug administration law, carried out emergency review and approval in accordance with the special examination and approval procedures of drugs. With the conditional approval of the Pfizer Inc COVID-19 viral therapeutic drug nemertave tablets / Ritonavir Tablets combination packaging (Paxlovid) import book, it was used to treat patients with mild to moderate New Coronavirus pneumonia (COVID-19) accompanied by progressive severe risk factors, such as those with advanced age. Patients with severe risk factors such as chronic kidney disease, diabetes, cardiovascular disease and chronic lung disease.
In March 15th, the national health and Health Committee released the New Coronavirus pneumonia diagnosis and treatment plan (trial version ninth). The main points of revision showed that the specific anti Paxlovid COVID-19 drugs approved by the State Administration of drug administration were written into the treatment plan.
On March 18, China Meheco Group Co.Ltd(600056) ( China Meheco Group Co.Ltd(600056) ) issued a change announcement, saying that on March 17, the company completed the import customs clearance procedures of the first batch of this product and is fully cooperating with the state in the fight against covid-19 epidemic. The final use and sales of the product are greatly uncertain due to factors such as epidemic prevention and control, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance.
From March 2 to March 18, 6 Shanxi Fenghuo Electronics Co.Ltd(000561) 3 trading days, the stock price has increased by 10 times, and the cumulative increase of the stock price is nearly 200%. As of the closing on March 18, China Meheco Group Co.Ltd(600056) rose by the limit to close at 33.26 yuan, with a market value of 35.54 billion yuan.
